System and method for augmenting a humoral immune response

• US 20080033707A1
• Filed: 08/28/2007
• Published: 02/07/2008
• Est. Priority Date: 08/24/2004
• Status: Abandoned Application

• Current Assignee: Searete LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Jung, Edward, Wilson, Richa, Myhrvold, Nathan, Wood, Lowell, Ishikawa, Muriel
• Application Number:
  US11/897,104
• Publication Number:
  US 20080033707A1
• Time in Patent Office: Days
• US Class Current: 703/11
• CPC Class Codes: A61K 31/55 having seven-membered rings, e.g. azelastine, pentylenetetrazole
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/02 Bacterial antigens
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present application relates, in general, to a system and/or method for detection and/or treatment.

Claims

1-52. -52. (canceled)

53. A computer-implemented method, comprising:

identifying an association of at least one computable antigen of one or more agents with at least a part of an immune response;

projecting a pattern of one or more changes relating to the at least one computable antigen of the one or more agents; and

selecting one or more immune response components in response to the projecting.

61. The method of claim 53, wherein the identifying an association of at least one computable antigen of one or more agents with at least a part of an immune response comprises:

identifying an association of at least one computable antigen with one or more agents wherein at least one of the one or more agents is a putative causative agent of a disease.

62. The method of claim 53, wherein the identifying an association of at least one computable antigen of one or more agents with at least a part of an immune response comprises:

identifying an association of at least one computable antigen with one or more agents wherein at least one of the one or more agents is an agent belonging to the same family or group as the agent of primary interest.

63. The method of claim 53, wherein the identifying an association of at least one computable antigen of one or more agents with at least a part of an immune response comprises:

identifying an association of at least one computable antigen with one or more agents wherein at least one of the one or more agents is an agent exhibiting a common function relative to the agent of primary interest.

66. The method of claim 53, wherein the selecting one or more immune response components in response to the projecting comprises:

selecting at least a part of at least one B-lymphocyte.

67. The method of claim 53, wherein the selecting one or more immune response components in response to the projecting comprises:

selecting one or more modulators of at least a part of a B-lymphocyte.

70. The method of claim 53, wherein the selecting one or more immune response components in response to the projecting comprises:

selecting one or more immune response components specific to a conformational state of a protein.

71. The method of claim 53, wherein the selecting one or more immune response components in response to the projecting comprises:

selecting one or more immune response components including one or more effector molecules.

72. The method of claim 53, wherein the selecting one or more immune response components in response to the projecting comprises:

selecting one or more immune response components with physico-chemical properties optimized by computer-based screening methods.

73. The method of claim 53, wherein the selecting one or more immune response components in response to the projecting comprises:

selecting one or more immune response components designed to include accommodations in its design arising from the prediction of mutational changes in an epitope.

74. The method of claim 53, wherein the selecting one or more immune response components in response to the projecting comprises:

selecting one or more immune response components designed for binding to the smallest effective determinant.

54. (canceled)

55. A computer-implemented method, comprising:

accepting an input of one or more agents; and

identifying an association of at least one computable antigen of one or more agents with at least a part of an immune response related to suppressing the one or more agents.

75. The method of claim 55, wherein the accepting an input of one or more agents comprises:

accepting input via a medical system.

76. The method of claim 55, wherein the accepting an input of one or more agents comprises:

accepting input including criteria related to the agent.

78. The method of claim 55, wherein the identifying an association of at least one computable antigen of one or more agents with at least a part of an immune response comprises:

identifying an association of at least one computable antigen with one or more agents wherein at least one of the one or more agents is a putative causative agent of a disease.

79. The method of claim 55, wherein the identifying an association of at least one computable antigen of one or more agents with at least a part of an immune response comprises:

identifying an association of at least one computable antigen with one or more agents wherein at least one of the one or more agents is an agent belonging to the same family or group as the agent of primary interest.

80. The method of claim 55, wherein the identifying an association of at least one computable antigen of one or more agents with at least a part of an immune response comprises:

identifying an association of at least one computable antigen with one or more agents wherein at least one of the one or more agents is an agent exhibiting a common function relative to the agent of primary interest.

56. (canceled)

57. A computer-implemented method, comprising:

projecting a pattern of one or more changes relating to at least one computable antigen of one or more agents; and

selecting one or more immune response components in response to said projecting.

83. The method of claim 57, wherein the selecting one or more immune response components in response to the projecting comprises:

selecting at least a part of at least one B-lymphocyte.

84. The method of claim 57, wherein the selecting one or more immune response components in response to the projecting comprises:

selecting one or more modulators of at least a part of a B-lymphocyte.

87. The method of claim 57, wherein the selecting one or more immune response components in response to the projecting comprises:

selecting one or more immune response components specific to the conformational state of a protein.

88. The method of claim 57, wherein the selecting one or more immune response components in response to the projecting comprises:

selecting one or more immune response components including one or more effector molecules.

89. The method of claim 57, wherein the selecting one or more immune response components in response to the projecting comprises:

selecting one or more immune response components with physico-chemical properties optimized by computer-based screening methods.

90. The method of claim 57, wherein the selecting one or more immune response components in response to the projecting comprises:

selecting one or more immune response components designed to include accommodations in its design arising from the prediction of mutational changes in an epitope.

91. The method of claim 57, wherein the selecting one or more immune response components in response to the projecting comprises:

selecting one or more immune response components designed for binding to the smallest effective determinant.

58. (canceled)

59. (canceled)

60. (canceled)

64. (canceled)

65. (canceled)

68. (canceled)

69. (canceled)

77. (canceled)

81. (canceled)

82. (canceled)

85. (canceled)

86. (canceled)